Medicenna Stock Story

MDNA
 Stock
  

USD 1.05  0.05  5.00%   

Medicenna Therapeutics Current Ratio is projected to increase significantly based on the last few years of reporting. The past year's Current Ratio was at 11.80. The current year Debt to Equity Ratio is expected to grow to 0.1, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (16.7 M). Medicenna Therapeutics is scheduled to announce its earnings tomorrow. As many risky investors are excited about healthcare space, it is only fair to go over Medicenna Therapeutics Corp based on its current volatility. We will evaluate why recent Medicenna Therapeutics price moves suggest a bounce in July. The company almost mirrors the market. We can now analyze Medicenna as a potential investment option for your portfolios.
Published over a month ago
View all stories for Medicenna Therapeutics | View All Stories

Are Medicenna Therapeutics (NASDAQ:MDNA) weak basic indicators contributing to the current slip?

We provide investment recommendation to complement the last-minute expert consensus on Medicenna Therapeutics Corp. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Medicenna Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Medicenna Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Medicenna Therapeutics investors may use each financial statement separately, they are all related. The changes in Medicenna Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Medicenna Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Medicenna Therapeutics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Medicenna Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Medicenna Therapeutics shares is the value that is considered the true value of the share. If the intrinsic value of Medicenna is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Medicenna Therapeutics.
Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring Medicenna Therapeutics on a daily basis if you are holding a position in it. Medicenna Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Medicenna Therapeutics stock to be traded above the $1 level to remain listed. If Medicenna Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

What is Medicenna Asset Breakdown?

Medicenna Therapeutics Corp reports assets on its Balance Sheet. It represents the amount of Medicenna resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Medicenna volatility, please check the breakdown of all its fundamentals

Are Medicenna Therapeutics Earnings Expected to grow?

The future earnings power of Medicenna Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Medicenna Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Medicenna Therapeutics stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Medicenna expected earnings.

Breaking it down a bit more

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Medicenna Therapeutics is not uncomon. Institutional investor usually refers to an organization that invests money in Medicenna Therapeutics on behalf of clients or other money managers. Buying and selling of large positions of Medicenna Therapeutics stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Medicenna Therapeutics stock. Let's take a look at how the ownership of Medicenna is distributed among investors.

Ownership Allocation

Medicenna Therapeutics maintains a total of fifty-three million nine hundred eighty thousand outstanding shares. Medicenna Therapeutics Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.


Retail Investors
59.48%
Insiders
33.16%
Institutions
7.36%
Retail Investors59.48
Insiders33.16
Institutions7.36
 2019 2020 2021 2022 (projected)
Current Assets37.85 M42.15 M48.47 M41.94 M
Total Assets38 M42.25 M48.59 M42.06 M

Asset Utilization

One of the ways to look at asset utilization of Medicenna is to check how much profit was generated for every dollar of assets it reports. Medicenna Therapeutics Corp secures a negative usage of assets of -50.17 %, losing $0.5 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Medicenna Therapeutics Corp shows how discouraging it operates for each dollar spent on its assets.


Current Assets
41.9 M
Current Assets41.94 Million99.55
Assets Non Current125,6800.3
Goodwill65,660.350.16

Our Medicenna analysis suggests possible reversion in July

The information ratio is down to -0.13 as of today. Medicenna Therapeutics Corp exhibits very low volatility with skewness of 0.79 and kurtosis of 2.51. However, we advise investors to further study Medicenna Therapeutics Corp technical indicators to make sure all market info is available and is reliable. Medicenna Therapeutics Corp is a potential penny stock. Although Medicenna Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Medicenna Therapeutics Corp. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Medicenna instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Take On Medicenna Therapeutics

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Medicenna may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 21st of June 2022, our final 90 days buy-sell recommendation on the company is Cautious Hold. We believe Medicenna Therapeutics is undervalued with quite high probability of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Medicenna Therapeutics Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com